PharmaLundensis Investor Relations Material
Latest events
Q1 2025
15 May, 2025
Q4 2024
12 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PharmaLundensis
Access all reports
PharmaLundensis AB is a Sweden-based biotechnology company focused on developing treatments and solutions for respiratory diseases. The company specializes in research aimed at addressing chronic obstructive pulmonary disease (COPD) and related conditions. In addition to its pharmaceutical development activities, PharmaLundensis explores environmentally friendly methods for reducing medical waste and chemical emissions in healthcare. The company is headquartered in Lund, Sweden, and its shares are listed on the Spotlight Stock Market.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
PHAL
Country
🇸🇪 Sweden